More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.
The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise.
Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbus
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh